scispace - formally typeset
N

Neil C. Barman

Researcher at Monash University

Publications -  12
Citations -  2674

Neil C. Barman is an academic researcher from Monash University. The author has contributed to research in topics: Blood pressure & Denervation. The author has an hindex of 8, co-authored 11 publications receiving 2427 citations.

Papers
More filters
Journal ArticleDOI

Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): A randomised controlled trial

TL;DR: Catheter-based renal denervation can safely be used to substantially reduce blood pressure in treatment-resistant hypertensive patients and should be continued, according to the authors.
Patent

Methods for Therapeutic Renal Denervation

TL;DR: In this paper, the authors proposed methods that block, reduce and/or inhibit renal sympathetic nerve activity to achieve a reduction in central sympathetic tone, which may carry several therapeutic benefits across many disease states.
Journal ArticleDOI

Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial.

Michel Azizi, +245 more
- 26 Jun 2021 - 
TL;DR: In this article, the authors evaluated the efficacy and safety of endovascular renal denervation in patients with hypertension resistant to three or more antihypertensive medications including a diuretic.
Journal ArticleDOI

Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial

Michel Azizi, +129 more
- 28 May 2019 - 
TL;DR: The BP lowering effect of endovascular ultrasound RDN was maintained at 6 months with less prescribed antihypertensive medications compared with a sham control, and safety was maintained.
Patent

Methods for Treating sleep apnea via renal Denervation

TL;DR: In this article, the authors proposed a method to block, reduce and/or inhibit renal sympathetic nerve activity to achieve a reduction in central sympathetic tone, which may carry several therapeutic benefits across many disease states, including, but without limitation, insulin resistance, diabetes and metabolic syndrome.